Due to a gene defect (Lps(d)), C3H/HeJ mice are known to be hyporesponsive to the immunobiological potential of lipopolysaccharide (LPS). We studied dose requirements for LPS, IFN-gamma, and cytokines TNF-alpha and IL-10 to produce nitric oxide (NO) in peritoneal macrophages (Mphi) from these animals. In contrast to the Lps(n) C3H/HeN mice, high concentrations of LPS (up to 5 microg/mL) or IFN-gamma (up to 5 ng/mL) by themselves were unable to activate NO production in C3H/HeJ Mphi. The failure to produce NO could not be overcome by addition of L-arginine or tetrahydropterin. The high-output NO biosynthesis was dose-dependently stimulated by combined administration of varying concentrations of IFN-gamma (50-5000 pg/mL) and LPS (approximately 1 ng/mL) or to a lesser extent by IFN-gamma plus TNF-alpha or TNF-alpha/IL-10. Formation of NO in C3H/HeJ MCO triggered by high concentration of LPS (approximately 1 microg/mL) given together with IFN-gamma (0.2-5 ng/mL) reached the values typical for Lps(n) C3H/HeN mice. While Mphi from C3H/HeN mice secreted TNF-alpha, IL-10, and IL-10 upon contact with a low dose of LPS (1 ng/mL), C3H/HeJ Mphi required high concentration of LPS (5 microg/mL) to enhance the secretion of the cytokines. Yet, this dose remained ineffective to stimulate IFN-gamma in Mphi from C3H/HeJ mice. It can be presumed that one of the important factors influencing their deficient ability to form NO is a failure of Mphi to produce IFN-gamma upon LPS contact.

Department of Immunopharmacology Institute of Experimental Medicine Academy of Sciences of the Czech Republic 142 20 Prague Czechia

Zobrazit více v PubMed

Infect Immun. 1995 Feb;63(2):601-8 PubMed

Adv Immunol. 1979;28:293-450 PubMed

Infect Immun. 1996 Apr;64(4):1309-13 PubMed

Environ Health Perspect. 1997 Sep;105 Suppl 5:1297-300 PubMed

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11543-8 PubMed

J Leukoc Biol. 1992 May;51(5):501-6 PubMed

Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8676-80 PubMed

Infect Immun. 1991 Nov;59(11):4049-55 PubMed

Immunol Lett. 1996 Aug;52(1):1-7 PubMed

Biochem Biophys Res Commun. 1994 Apr 15;200(1):126-34 PubMed

J Immunol. 1980 Apr;124(4):2004-9 PubMed

J Exp Med. 1986 Dec 1;164(6):1876-88 PubMed

Cytokine. 1998 Feb;10(2):115-23 PubMed

FEMS Immunol Med Microbiol. 1996 Mar;13(3):235-8 PubMed

Eur J Immunol. 1991 Dec;21(12):3009-14 PubMed

J Biol Chem. 1997 Jun 6;272(23):14899-907 PubMed

Folia Microbiol (Praha). 2002;47(6):709-16 PubMed

Eur Respir J. 2001 Oct;18(4):667-71 PubMed

Cell Growth Differ. 1991 Aug;2(8):401-7 PubMed

Infect Immun. 1997 Nov;65(11):4822-31 PubMed

Immunobiology. 1993 Apr;187(3-5):233-56 PubMed

J Immunol. 1992 May 1;148(9):2853-8 PubMed

J Immunol. 1993 Jun 1;150(11):5033-40 PubMed

J Exp Med. 1995 May 1;181(5):1743-54 PubMed

Blood. 1995 Aug 1;86(3):1184-95 PubMed

J Immunol Methods. 1994 Sep 14;174(1-2):231-5 PubMed

Immunity. 1994 Sep;1(6):509-16 PubMed

Infect Immun. 1985 May;48(2):464-73 PubMed

J Clin Invest. 1992 Mar;89(3):867-77 PubMed

Immunobiology. 1999 Jun;200(2):169-86 PubMed

Cell. 1989 Aug 25;58(4):729-39 PubMed

Biochem Biophys Res Commun. 1993 Jul 30;194(2):826-35 PubMed

Mol Cell Biol. 1993 Aug;13(8):4531-8 PubMed

J Interferon Cytokine Res. 1998 Aug;18(8):549-54 PubMed

Infect Immun. 1994 Sep;62(9):3663-71 PubMed

Proc Natl Acad Sci U S A. 1989 Dec;86(24):9936-40 PubMed

Int Immunol. 1993 Nov;5(11):1383-92 PubMed

Transplantation. 1995 Oct 15;60(7):707-13 PubMed

Nature. 1968 Sep 21;219(5160):1253-4 PubMed

Science. 1994 Mar 18;263(5153):1612-5 PubMed

Nature. 1991 Jul 25;352(6333):342-4 PubMed

J Exp Med. 1997 Jun 16;185(12):2095-100 PubMed

Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):522-6 PubMed

J Exp Med. 1992 Aug 1;176(2):485-94 PubMed

Science. 1990 Sep 21;249(4975):1431-3 PubMed

Biochem Pharmacol. 1992 Jun 9;43(11):2401-6 PubMed

Vet Immunol Immunopathol. 1995 Feb;44(3-4):269-78 PubMed

J Exp Med. 1999 Feb 15;189(4):615-25 PubMed

Int J Cancer. 1980 Jan 15;25(1):159-68 PubMed

J774 macrophage-like cell line cytokine and chemokine patterns are modulated by Francisella tularensis LVS strain infection

Immunomodulatory effects of Bacillus firmus on mouse peritoneal cells in vitro

Intratracheal and intranasal immunization with ovalbumin conjugated with Bacillus firmus as a carrier in mice

Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis